drugset / Trial / NCT04218981
Definitive Selection of Neuroimaging Biomarkers for the Diagnosis and Treatment to Common Mental Disorders
Non-randomizedParallel-groupQuadruple-blindDiagnostic
Summary
To explore the whole-brain anatomical and functional abnormalities in drug-naive patients with schizophrenia ,drug-naive patients with BD, drug-naive patients with MDD and healthy controls by using a combination of cross-sectional and longitudinal study designs, including a longitudinal study with 8 weeks of drugs treatment. And explore whether there are shared imaging biomarkers between these three common mental disorders.
Timeline
- Start
- 2020-01-15
- Primary completion
- 2023-06-25
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amisulpride | Small molecule | — | — |
| Subject | Lithium | Unknown | — | — |
| Subject | Olanzapine | Small molecule | — | — |
| Subject | Paroxetine | Small molecule | — | — |
| Subject | Risperidone | Other / unclassified | — | — |
| Subject | Valproate | Small molecule | — | — |